R
Raveen Rathnasinghe
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 42
Citations - 2394
Raveen Rathnasinghe is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Medicine & Virus. The author has an hindex of 12, co-authored 30 publications receiving 1037 citations. Previous affiliations of Raveen Rathnasinghe include Mount Sinai Health System.
Papers
More filters
Journal ArticleDOI
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.
Laura Riva,Shuofeng Yuan,Xin Yin,Laura Martin-Sancho,Naoko Matsunaga,Lars Pache,Sebastian Burgstaller-Muehlbacher,Paul D. De Jesus,Peter Teriete,Mitchell V. Hull,Max W. Chang,Jasper Fuk-Woo Chan,Jianli Cao,Vincent Kwok-Man Poon,Kristina M. Herbert,Kuoyuan Cheng,Kuoyuan Cheng,Tu Trinh H. Nguyen,Andrey Rubanov,Yuan Pu,Courtney Nguyen,Angela Choi,Raveen Rathnasinghe,Michael Schotsaert,Lisa Miorin,Marion Dejosez,Thomas P. Zwaka,Ko Yung Sit,Luis Martinez-Sobrido,Wen-Chun Liu,Kris M. White,Mackenzie E. Chapman,Emma K. Lendy,Richard Glynne,Randy A. Albrecht,Eytan Ruppin,Andrew D. Mesecar,Jeffrey R Johnson,Christopher Benner,Ren Sun,Peter G. Schultz,Andrew I. Su,Adolfo García-Sastre,Arnab K. Chatterjee,Kwok-Yung Yuen,Sumit K. Chanda +45 more
TL;DR: A screen of the ReFRAME library of approximately 12,000 known drugs for antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) identified several candidate compounds with suitable activities and pharmacological profiles, which could potentially expedite the deployment of therapies for coronav virus disease 2019 (COVID-19).
Journal ArticleDOI
SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling.
Lisa Miorin,Thomas Kehrer,Maria Teresa Sánchez-Aparicio,Ke Zhang,Phillip Cohen,Roosheel S. Patel,Anastasija Cupic,Tadashi Makio,Menghan Mei,Elena Moreno,Oded Danziger,Kris M. White,Raveen Rathnasinghe,Melissa B. Uccellini,Shengyan Gao,Teresa Aydillo,Ignacio Mena,Xin Yin,Laura Martin-Sancho,Nevan J. Krogan,Nevan J. Krogan,Nevan J. Krogan,Sumit K. Chanda,Michael Schotsaert,Richard W. Wozniak,Yi Ren,Brad R. Rosenberg,Beatriz M. A. Fontoura,Adolfo García-Sastre +28 more
TL;DR: SARS-CoV-2 is able to efficiently block STAT1 and STAT2 nuclear translocation in order to impair transcriptional induction of IFN-stimulated genes (ISGs).
Journal ArticleDOI
SARS-CoV-2 spike E484K mutation reduces antibody neutralisation.
Sonia Jangra,Chengjin Ye,Raveen Rathnasinghe,Daniel Stadlbauer,Florian Krammer,Viviana Simon,Luis Martinez-Sobrido,Adolfo García-Sastre,Michael Schotsaert +8 more
Journal ArticleDOI
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.
Kris M. White,Romel Rosales,Soner Yildiz,Thomas Kehrer,Lisa Miorin,Elena Moreno,Sonia Jangra,Melissa B. Uccellini,Raveen Rathnasinghe,Lynda Coughlan,Carles Martínez-Romero,Jyoti Batra,Ajda Rojc,Mehdi Bouhaddou,Jacqueline M. Fabius,Kirsten Obernier,Marion Dejosez,Maria Jose Guillen,Alejandro Losada,Pablo Aviles,Michael Schotsaert,Thomas P. Zwaka,Marco Vignuzzi,Kevan M. Shokat,Nevan J. Krogan,Adolfo García-Sastre +25 more
TL;DR: In this article, the authors showed that plitidepsin (aplidin) possesses antiviral activity (90% inhibitory concentration = 0.88 nM) that is more potent than remdesivir against SARS-CoV-2 in vitro by a factor of 27.5.
Journal ArticleDOI
Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection
Raveen Rathnasinghe,Shirin Strohmeier,Fatima Amanat,Virginia L. Gillespie,Florian Krammer,Adolfo García-Sastre,Lynda Coughlan,Lynda Coughlan,Michael Schotsaert,Melissa B. Uccellini +9 more
TL;DR: The K18-hACE2 model provides a stringent model for testing vaccines and antivirals, whereas the adenovirus delivery system has the flexibility to be used across multiple genetic backgrounds and modified mouse strains.